Status:
COMPLETED
Lymphocyte Count, ATG Dose and Incidence and Severity of GVHD in Pediatric Recipients of HSCT
Lead Sponsor:
IRCCS Burlo Garofolo
Conditions:
Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
1-17 years
Brief Summary
Despite increasing success rate in hematopoietic stem cell transplantation (HSCT) control of graft versus host disease (GVHD) remains a significative burden in mortality and morbidity. A lot of strate...
Eligibility Criteria
Inclusion
- Age of the patients between 0 and 17
- Diagnosis of hematological or oncological disease undergoing allogeneic bone marrow transplantation
- Patients undergoing myeloablative conditioning
- Patients that received ATG as GVHD prophylaxis
- Patients whose consent has already been acquired for the processing of data for research purposes
- Minimum follow-up of 12 months
Exclusion
- Bacterial and / or fungal infection present at the time of bone marrow transplantation
- Use of Thymoglobulin in the 3 months prior to transplantation
- Allergy and / or intolerance to the active substances or excipients contained in Thymoglobulin
Key Trial Info
Start Date :
January 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04869254
Start Date
January 1 2000
End Date
December 31 2020
Last Update
May 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Maternal and Child Health - IRCCS "Burlo Garofolo"
Trieste, Italy, 34137